The vesicular monoamine transporter-2: An important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 71-106

  Nickell, Justin R ^a   Siripurapu, Kiran B ^a   Vartak, Ashish ^a   Crooks, Peter A ^a   Dwoskin, Linda P ^a  

^a University of Kentucky   (United States)

Author keywords

AV 2 192; GZ 793A; Lobelane; Lobeline; Methamphetamine; VMAT2

Indexed keywords

1 METHYL 2,5 DI(2 BENZYL)PYRROLIDINE; 2,5 DI(2 BENZYL)PYRROLIDINE; 3 [2,6 DI(4 METHOXYPHENETHYL)PIPERIDIN 1 YL]PROPANE 1,2 DIOL; 3,5 BIS(2,4 DICHLOROBENZYLIDENE) 1 METHYLPIPERIDINE; ALKALOID DERIVATIVE; AV 1 227A; AV 1 227B; AV 1 229A; AV 2 192; AV 2 195; AV 2 197; AV 2 241; AV 2 252A; AV 2 256B; AV 3 155A; AV 3 156A; AV 3 158; AV 3 159; AV 3 161; AV 3 162; AV 3 165; GZ 793A; LOBELANE; LOBELINE; MESO RANSDIENE; MESO TRANSDIENE; METHAMPHETAMINE; PYRROLIDINE DERIVATIVE; RESERPINE; TETRABENAZINE; UKCP 110; UKMH 105; UKMH 106; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; DRUG TARGETING; DRUG TOLERANCE; HUMAN; IN VITRO STUDY; LOBELIA; METHAMPHETAMINE DEPENDENCE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

AV-2-192; GZ-793A; LOBELANE; LOBELINE; METHAMPHETAMINE; VMAT2;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; LOBELINE; METHAMPHETAMINE; PROTEIN BINDING; TREATMENT OUTCOME; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84893179195     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00002-0     Document Type: Chapter

References (99)

1. Alvers K.M., Beckmann J.S., Zheng G., Crooks P.A., Dwoskin L.P., Bardo M.T. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology 2012, 224:255-262.
2. 3H]GBR 12935 binding in vitro to rat striatal membranes: Labeling of the dopamine uptake complex. Journal of Neurochemistry 1987, 48:1887-1896.
3. 3H-dopamine in synaptic vesicles. Life Sciences 1980, 26:575-578.
4. Barlow R.B., Johnson O. Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds. British Journal of Pharmacology 1989, 98:799-808.
5. Beckmann J.S., Denehy E.D., Zheng G., Crooks P.A., Dwoskin L.P., Bardo M.T. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology 2012, 220:295-403.
6. Beckmann J.S., Siripurapu K.B., Nickell J.R., Horton D.B., Denehy E.D., Vartak A., et al. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics 2010, 335:841-851.
7. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: Inhibition of mitochondrial respiration. Journal of Neurochemistry 1995, 64:718-723.
8. Brown J.M., Hanson G.R., Fleckenstein A.E. Methamphetamine rapidly decreases vesicular dopamine uptake. Journal of Neurochemistry 2000, 74:2221-2223.
9. Brown J.M., Hanson G.R., Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. The Journal of Pharmacology and Experimental Therapeutics 2001, 296:762-767.
10. Carr G.D., White N.M. Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections. Life Sciences 1983, 33:2551-2557.
11. Chaudhry F.A., Edwards R.H., Fonnum F. Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. Annual Review of Pharmacology and Toxicology 2008, 48:277-301.
12. Damaj M.I., Patrick G.S., Creasy K.R., Martin B.R. Pharmacology of lobeline, a nicotinic receptor ligand. The Journal of Pharmacology and Experimental Therapeutics 1997, 282:410-419.
13. Darchen F., Scherman D., Henry J.P. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 1989, 28:1692-1697.
14. DASIS, Drug and Alcohol Services Information System (DASIS) (2008). The DASIS Report. Primary methamphetamine/amphetamine admissions to substance abuse treatment: 2005. http://www.oas.samhsa.gov/2k8/methamphetamineTx/meth.htm.
15. Di Chiara G., Bassareo V., Fenu S., De Luca M.A., Spina L., Cadoni C., et al. Dopamine and drug addiction: The nucleus accumbens shell connection. Neuropharmacology 2004, 47:227-241.
16. Dwoskin L.P., Crooks P.A. A novel mechanism and potential use for lobeline as a treatment for psychostimulant abuse. Biochemical Pharmacology 2002, 63:89-98.
17. Eiden L.E., Weihe E. VMAT2: A dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences 2011, 1216:86-98.
18. Erickson J.D., Eiden L.E., Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:10993-10997.
19. Erickson J.D., Schafer M.K., Bonner T.I., Eiden L.E., Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:5166-5171.
20. Finn J.P., Edwards R.H. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. The Journal of Biological Chemistry 1997, 272:16301-16307.
21. Fischer J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: Evidence for an exchange diffusion model. The Journal of Pharmacology and Experimental Therapeutics 1979, 208:203-209.
22. Flammia D., Dukat M., Damaj M.I., Martin B., Glennon R.A. Lobeline: Structure-affinity investigation of nicotinic acetylcholinergic receptor binding. Journal of Medicinal Chemistry 1999, 42:3726-3731.
23. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology 2007, 47:681-698.
24. Fon E.A., Pothos E.N., Sun B., Killeen N., Sulzer D., Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997, 19:1271-1283.
25. Frey K.A., Koeppe R.A., Kilbourn M.R., Vander Borght T.M., Albin R.L., Gilman S., et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Annals of Neurology 1996, 40:873-884.
26. Frize E.D. Mental depression in hypertensive patients treated for long periods with high doses of reserpine. The New England Journal of Medicine 1954, 251:1006-1008.
27. Glatt C.E., DeYoung J.A., Delgado S., Service S.K., Giacomini K.M., Edwards R.H., et al. Screening a large reference sample to identify very low frequency sequence variants: Comparison between two genes. Nature Genetics 2001, 27:435-438.
28. Glatt C.E., Wahner A.D., White D.J., Ruiz-Linares A., Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Human Molecular Genetics 2006, 15:299-305.
29. Han D.D., Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology 2006, 6:6.
30. Hart C.L., Ward A.S., Haney M., Foltin R.W., Fischman M.W. Methamphetamine self-administration by humans. Psychopharmacology 2001, 157:75-81.
31. Harrod S.B., Dwoskin L.P., Crooks P.A., Klebaur J.E., Bardo M.T. Lobeline attenuates d-methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics 2001, 298:172-179.
32. Harrod S.B., Dwoskin L.P., Green T.A., Gehrke B.J., Bardo M.T. Lobeline does not serve as a reinforcer in rats. Psychopharmacology 2003, 165:397-404.
33. Hastings T.G., Lewis D.A., Zigmond M.F. Reactive dopamine metabolites and neurotoxicity: Implications for Parkinson's disease. Advances in Experimental Medicine and Biology 1996, 387:97-106.
34. Henry J.P., Gasnier B., Roisin M.P., Isamber M.F., Scherman D. Molecular pharmacology of the monoamine transporter of the chromaffin granule membrane. Annals of the New York Academy of Sciences 1987, 493:194-206.
35. Hillarp N.A. The release of catechol amines from the amine containing granules of the adrenal medulla. Acta Physiologica Scandinavica 1958, 43:292-302.
36. Hiroi N., White N.M. The lateral nucleus of the amygdala mediates expression of the amphetamine produced conditioned place preference. The Journal of Neuroscience 1991, 11:2107-2116.
37. Hoebel B.G., Monaco A.P., Hernandez L., Aulisi E.F., Stanley B.G., Lenard L. Self-injection of amphetamine directly into the brain. Psychopharmacology 1983, 81:158-163.
38. Hogan K.A., Staal R.G., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations. Journal of Neurochemistry 2000, 74:2217-2220.
39. Horton D.B., Nickell J.R., Zheng G., Crooks P.A., Dwoskin L.P. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. Journal of Neurochemistry 2013, 127:177-186.
40. Horton D.B., Siripurapu K.B., Norrholm S.D., Culver J.P., Hojahmat M., Beckmann J.S., et al. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics 2011, 336(3):940-951.
41. Horton D.B., Siripurapu K.B., Zheng G., Crooks P.A., Dwoskin L.P. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics 2011, 339:286-297.
42. Johnson R.G. Accumulation of biological amines into chromaffin granules: A model for hormone and neurotransmitter transport. Physiological Reviews 1988, 68:232-307.
43. Johnson R.A., Eshleman A.J., Meyers T., Neve K.A., Janowsky A. Substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse 1998, 30:97-106.
44. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research. Brain Research Reviews 1991, 16:223-244.
45. Kanner B.I., Schuldiner S. Mechanism of transport and storage of neurotransmitters. CRC Critical Reviews in Biochemistry 1987, 22:1-38.
46. Kazumata K., Dhawan V., Chaly T., Antonini A., Marqouleff C., Belakhlef A., et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. Journal of Nuclear Medicine 1998, 39:1521-1530.
47. 11H]dihydrotetrabenazine binding in rat striatum: Sensitivity to dopamine concentrations. Nuclear Medicine and Biology 2010, 37:3-8.
48. Kilbourn M., Lee L., Vander Borght T., Jewett D., Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. European Journal of Pharmacology 1995, 278:249-252.
49. Koob G.F. Neural mechanisms of drug reinforcement. Annals of the New York Academy of Sciences 1992, 654:171-191.
50. 3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochemical Pharmacology 1982, 31:983-992.
51. Liu Y., Edwards R.H. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annual Review of Neuroscience 1997, 20:125-156.
52. + toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
53. Liu Y., Roghani A., Edwards R.H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:9074-9078.
54. Lyness W.H., Friedle N.M., Moore K.E. Destruction of dopaminergic nerve terminals in nucleus accumbens: Effect on d-amphetamine self-administration. Pharmacology, Biochemistry, and Behavior 1979, 11:553-556.
55. Madras B.K., Meltzer P.C., Liang A.Y., Elmaleh D.R., Babich J., Fischman A.J. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 1998, 29:93-104.
56. Mantle T.J., Tipton K.F., Garrett N.J. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochemical Pharmacology 1976, 25:2073-2077.
57. Matecka D., Lewis D., Rothman R.B., Dersch M., Wojnicki F.H., Glowa J.R., et al. Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. Journal of Medicinal Chemistry 1997, 40:705-716.
58. Merickel A., Rosandich P., Peter D., Edwards R.H. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. The Journal of Biological Chemistry 1995, 270:25798-25804.
59. Meyer A.C., Neugebauer N.M., Zheng G., Crooks P.A., Dwoskin L.P., Bardo M.T. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. Journal of Neurochemistry 2013, 127:187-198.
60. + efflux from thalamic synaptosomes. Neuropharmacology 2000, 39:2654-2662.
61. Miller D.K., Crooks P.A., Teng L.H., Witkin J.M., Munzar P., Goldberg S.R., et al. Lobeline inhibits the neuronal and behavioral effects of amphetamine. The Journal of Pharmacology and Experimental Therapeutics 2001, 296:1023-1034.
62. Miller D.K., Crooks P.A., Zheng G., Grinevich V.P., Norrholm S.D., Dwoskin L.P. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters and diminished affinity at α4β2* and α7* nicotinic receptors. The Journal of Pharmacology and Experimental Therapeutics 2004, 310:1035-1045.
63. Miller G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporter and neuronal injury. Trends in Pharmacological Sciences 1999, 20:424-429.
64. Miller D.K., Green T.A., Harrod S.B., Bardo M.T., Crooks P.A., Dwoskin L.P. Effects of lobeline on methamphetamine and nicotine-induced hyperactivity and sensitization. Drug and Alcohol Dependence 2000, 60:151.
65. Naudon L., Raisman-Vozari R., Edwards R.H., Leroux-Nicollet I., Peter D., Liu Y., et al. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. The European Journal of Neuroscience 1996, 8:842-846.
66. Neugebauer N.M., Harrod S.B., Stairs D.J., Crooks P.A., Dwoskin L.P., Bardo M.T. Lobelane decreases methamphetamine self-administration in rats. European Journal of Pharmacology 2007, 571:33-38.
67. Nickell J.R., Krishnamurthy S., Norrholm S., Deaciuc G., Siripurapu K.B., Zheng G., et al. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. The Journal of Pharmacology and Experimental Therapeutics 2010, 332:612-621.
68. 3H]dopamine uptake at the vesicular monoamine transporter-2. The Journal of Pharmacology and Experimental Therapeutics 2011, 336(3):724-733.
69. Njus D., Kelley P.M., Harnadek G.J. Bioenergetics of secretory vesicles. Biochimica et Biophysica Acta 1986, 853:237-265.
70. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. The Journal of Neuropsychiatry and Clinical Neurosciences 2003, 15:317-325.
71. Partilla J.S., Dempsey A.G., Nagpal A.S., Blough B.E., Baumann M.H., Rothman R.B. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. The Journal of Pharmacology and Experimental Therapeutics 2006, 319:237-246.
72. Peter D., Jimenez J., Liu Y., Kim J., Edwards R.H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. The Journal of Biological Chemistry 1994, 269:7231-7237.
73. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., Edwards R.H. Differential expression of two vesicular monoamine transporters. The Journal of Neuroscience 1995, 15:6179-6188.
74. Philippu A., Beyer J. Dopamine and noradrenaline transport into subcellular vesicles of the striatum. Naunyn-Schmiedeberg's Archives of Pharmacology 1973, 278:387-402.
75. Pifl C., Drobny H., Reither H., Hornykiewicz O., Singer E.A. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter. Molecular Pharmacology 1995, 47:368-373.
76. Riddle E.L., Fleckenstein A.E., Hanson G.R. Role of monoamine transporters in mediating psychostimulant effects. The AAPS Journal 2005, 7:847-851.
77. Rothman R.B., Ayestas M.A., Dersch C.M., Baumann M.H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension. Circulation 1999, 100:869-875.
78. Sagne C., Isambert M.F., Vandekerckhove J., Henry J.P., Gasnier B. The photoactivatable inhibitor 7-azido-8-iodoketanserin labels the N terminus of the vesicular monoamine transporter from bovine chromaffin granules. Biochemistry 1997, 36:3345-3352.
79. Schuldiner S., Liu Y., Edwards R.H. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. The Journal of Biological Chemistry 1993, 268:29-34.
80. Sievert M.K., Ruoho A.E. Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. The Journal of Biological Chemistry 1997, 272:26049-26055.
81. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. The Journal of Neuroscience 1995, 15:4102-4108.
82. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., et al. VMAT2 knockout mice: Heterozygotes display reduced locomotion, and enhanced MPTP toxicity. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:9938-9943.
83. 3H]dopamine from rat striatal synaptic vesicles: Comparison with d-amphetamine. Journal of Neurochemistry 1998, 71:258-265.
84. Teng L., Crooks P.A., Sonsalla P.K., Dwoskin L.P. Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: Differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. The Journal of Pharmacology and Experimental Therapeutics 1997, 280:1432-1444.
85. Thiriot D.S., Ruoho A.E. Mutagenesis and derivatization of human monoamine vesicle transporter-2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. The Journal of Biological Chemistry 2001, 276:27304-27315.
86. Uhl G.R. Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Annals of Neurology 1998, 43:555-560.
87. Vezina P. D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. The Journal of Neuroscience 1996, 16:2411-2420.
88. Wang Y., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997, 19:1285-1296.
89. Weaver J.A., Deupree J.D. Conditions required for reserpine binding to the catecholamine transporter on chromaffin granule ghosts. European Journal of Pharmacology 1982, 80:437-438.
90. Weihe E., Schafer M.K., Erickson J.D., Eiden L.E. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. Journal of Molecular Neuroscience 1995, 5:149-164.
91. Wilhelm C.J., Johnson R.A., Eshleman A.J., Janowsky A. Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochemical Pharmacology 2008, 75:1411-1415.
92. Wilmouth C.E., Zheng G., Crooks P.A., Dwoskin L.P., Bardo M.T. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacology, Biochemistry, and Behavior 2013, 112:29-33.
93. Wimalasena K. Vesicular monoamine transporters: Structure-function, pharmacology and medicinal chemistry. Medicinal Research Reviews 2010, 31:483-519.
94. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychological Review 1987, 94:469-492.
95. Wise R.A., Hoffman D.C. Localization of drug reward mechanisms by intracranial injections. Synapse 1992, 10:247-263.
96. Xu D.D., Mo Z.X., Yung K.K., Yang Y., Leung A.W. Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats. Neurosignals 2008, 15:322-331.
97. Yokel R.A., Pickens R. Self-administration of optical isomers of amphetamine and methylamphetamine by rats. The Journal of Pharmacology and Experimental Therapeutics 1973, 187:27-33.
98. Zheng G., Dwoskin L.P., Deaciuc A.G., Norrholm S.D., Crooks P.A. Defunctionalized lobeline analogues: Structure-activity of novel ligands for the vesicular monoamine transporter. Journal of Medicinal Chemistry 2005, 48:5551-5560.
99. Zheng G., Dwoskin L.P., Deaciuc A.G., Zhu J., Jones M.D., Crooks P.A. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorganic & Medicinal Chemistry Letters 2005, 13:3899-3909.